$15.03
-0.31 (-2.02%)
Open$15.17
Previous Close$15.34
Day High$15.39
Day Low$14.57
52W High$16.24
52W Low$7.87
Volume—
Avg Volume109.3K
Market Cap199.05M
P/E Ratio—
EPS$-0.79
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+59.5% upside
Current
$15.03
$15.03
Target
$23.98
$23.98
$18.55
$23.98 avg
$27.85
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 104.20M | 116.14M | 23.45M |
| Net Income | -10,049,285 | -10,080,647 | 5.38M |
| Profit Margin | -9.6% | -9.2% | 22.9% |
| EBITDA | -5,245,811 | -5,554,525 | 8.65M |
| Free Cash Flow | — | — | 4.59M |
| Rev Growth | -10.3% | -10.3% | -4.1% |
| Debt/Equity | — | — | 0.39 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |